Efficacy Study of Strattera for Treating Attention Disorders in Traumatic Brain Injury (TBI)
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Atomoxetine is the only medication that is currently approved by the FDA for the treatment of
attention deficit hyperactivity disorder in adults. It has gained recent interest as an
alternative medication for treating attentional problems related to traumatic brain injury
(TBI), but it's effectiveness in this population has not been studied. There are a number of
advantages of Atomoxetine over traditional neuro-stimulant medications currently used for
attentional disorders after traumatic brain injury. This study will use a randomized
double-blind placebo-controlled crossover design to investigate the efficacy of atomoxetine
to improve attention, behavioral function, and depression in adults with TBI